Pharmaceuticals, Biotechnology and Life Sciences
BioMarin Pharmaceutical and Par Pharmaceutical have entered into a settlement agreement that resolves patent litigation in the United States (U.S.) related to BioMarin’s Kuvan 100mg oral tablets and powder for oral solution in 100mg packets.
Innovative UK poured almost a million pounds to a developer of cell therapies including hematopoietic cell replacement therapies, Plasticell.
Diplomat Pharmacy and Corizon Health have entered into three-year agreement according to which Diplomat will provide pharmacy services and dispense limited-distribution specialty drugs for Corizon Health’s clients and support its in-house mail-order pharmacy, PharmaCorr
Respira Therapeutics, a privately held pharmaceutical company developing innovative inhaled therapies to treat pulmonary hypertension and other pulmonary diseases, has entered into a strategic collaboration with United Therapeutics Corporation for the development and exclusive license of Respira’s inhaled drug-device product, RT234, for pulmonary hypertension indications in North America.
Roche has announced the global launch of the anti-p504s (SP116) Rabbit Monoclonal Primary Antibody2 for prostate cancer diagnosis.
U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Active Biotech for its investigational novel agent tasquinimod, for the treatment of multiple myeloma.
argenx has initiated a Phase II trial of ARGX-110 as a monotherapy in patients with relapsed/refractory cutaneous T-cell lymphoma (CTCL).
The U.S. Food and Drug Administration has approved Neurocrine Biosciences’s Ingrezza (valbenazine) capsules to treat adults with tardive dyskinesia.
Diplomat Pharmacy has appointed Atul Kavthekar as chief financial officer and treasurer, effective May 1, 2017.
Bristol-Myers Squibb and Apexigen, a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based therapeutics for the treatment of cancer, have started a clinical trial collaboration to evaluate Bristol-Myers Squibb’s Opdivo (nivolumab) in combination with Apexigen’s APX005M in patients with advanced solid tumors.